The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation. (Q52620370)
Jump to navigation
Jump to search
scientific article published on 11 January 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation. |
scientific article published on 11 January 2012 |
Statements
The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation. (English)
Pallavi Subramanian
Karim Hamesch
Xiaofeng Li
Klaus Dembowsky
Eric Chevalier
11 January 2012
107
2
356-368